Biotech Values

[genisi]

Oppenheimer MS survey:

Is the 18.6% figure the average of all of the surveyed neurologists or the average of the 73% who think Gilenia will have an impact?

The latter.

It will drop much more than that if the FDA approves generic Copaxone :- )

Let's say gilenia is a more real and immediate threat shall we?
Plus I'm willing to negotiate on the "real"part